Comparison of TaqManW Array Card and MYCOTBTM with conventional phenotypic susceptibility testing in MDR-TB

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 8, 2016, Pages 1105-1112

  Foongladda, S ^a   Banu, S ^b   Pholwat, S ^c   Gratz, J ^c   O Thong, S ^a   Nakkerd, N ^a   Chinli, R ^a   Ferdous, S S ^b   Rahman, S M M ^b   Rahman, A ^b   Ahmed, S ^b   Heysell, S ^c   Sariko, M ^d   Kibiki, G ^d   Houpt, Eric ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b International Center for Diarrheal Diseases and Research   (Bangladesh)

^c UNIVERSITY OF VIRGINIA   (United States)

^d KILIMANJARO CLINICAL RESEARCH INSTITUTE   (Tanzania)

Author keywords

Drug susceptibility testing; MDR TB; MIC

Indexed keywords

AMIKACIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ACCURACY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFECT; LABORATORY DEVICE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BANGLADESH; CLINICAL TRIAL; COMPARATIVE STUDY; DNA MICROARRAY; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TANZANIA; THAILAND; TIME FACTOR; WORKFLOW;

BANGLADESH; DNA MUTATIONAL ANALYSIS; GENOTYPE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TANZANIA; THAILAND; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORKFLOW;

EID: 84978208794     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.15.0896     Document Type: Article

References (21)

1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
2. BastosM L, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- And second-line drugs: An individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-1374.
3. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2014.11Geneva, Switzerland: WHO, 2014.
4. World Health Organization. Xpert MTB/RIF implementation manual: Technical and operational 'how-to'; practical considerations. Geneva, Switzerland: WHO, 2014.
5. World Health Organization. The use of molecular line probe assay for the detection of resistance to second-line antituberculosis drugs. WHO/HTM/TB/2013.01. Geneva, Switzerland: WHO, 2013.
6. Abuali MM, Katariwala R, LaBombardi VJ. Acomparison of the Sensititrew MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur JClin Microbiol Infect Dis 2012; 31: 835-839.
7. Hall L, Jude KP, Clark SL, et al. Evaluation of the Sensititre MYCOTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- And second-line agents. JClin Microbiol 2012; 50: 3732-3734.
8. Lee J, Armstrong DT, SsengoobaW, et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- And second-line drugs. Antimicrob Agents Chemother 2014; 58: 11-18.
9. Pholwat S, Liu J, Stroup S, et al. Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes. mBio 2015; 6: E02273.
10. Van Deun A, Aung KJ, Bola V, et al. Rifampin drug resistance tests for tuberculosis: Challenging the gold standard. JClin Microbiol 2013; 51: 2633-2640.
11. Kambli P, Ajbani K, Sadani M, et al. Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the GenoType MTBDRsl assay. Tuberculosis (Edinb) 2015; 95: 137-141.
12. Kambli P, Ajbani K, Sadani M, et al. Defining multidrugresistant tuberculosis: Correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations. Diagn Microbiol Infect Dis 2015; 82: 49-53.
13. Willby M, Sikes RD, Malik S, Metchock B, Posey JE. Correlation between gyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 5427-5434.
14. Madison B, Robinson-Dunn B, George I, et al. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. JClin Microbiol 2002; 40: 3976-3979.
15. Miller WC. Can we do better than discrepant analysis for new diagnostic test evaluation? Clin Infect Dis 1998; 27: 1186-1193.
16. Heysell S, Pholwat S, Mpagama S, et al. Sensititre MYCOTB MIC plate compared to Bactec MGIT 960 for first and secondline anti-tuberculosis drug susceptibility testing in Tanzania: A call to operationalize minimum inhibitory concentrations. Antimicrob Agents Chemother 2015; 59: 7104-7108.
17. Banu S, Rahman SM, Khan MS, et al. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. JClin Microbiol 2014; 52: 156-163.
18. Zaczek A, Brzostek A, Augustynowicz-Kopec E, Zwolska Z, Dziadek J. Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol 2009; 9: 10.
19. Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. JClin Microbiol 2014; 52: 2157-2162.
20. Sirgel FA,Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. JAntimicrob Chemother 2012; 67: 1088-1093.
21. Williamson DA, Roberts SA, Bower JE, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int JTuberc Lung Dis 2012; 16: 216-220.